twofer opportun initi outperform
initi coverag biohaven pharmaceut outperform
rate price target primari focu remain compani
migrain pipelin stock offer multipl valu driver believ
reflect current trade level outperform thesi partial base
under-the-radar glutam platform two late stage asset well cgrp
receptor antagonist platform rimegep lead acknowledg
competit market dynam surround mechan believ
pursu indic larg therapeut area accommod multipl
player like diversifi portfolio manag clinic strategi note
clariti commerci front could becom import pipelin near
glutam platform offer multipl shot goal bhvn glutam
troriluzol nmda receptor antagonist troriluzol
could becom import valu driver next year acknowledg
sever mileston need met believ troriluzol revenu potenti
neuropsychiatri neurodegen indic ocd alzheim
underappreci current trade level
seat cgrp tabl estim us episod migrain patient may
avail treatment cgrp receptor antagonist believ
develop strategi could address variou patient need await clariti
commerci strategi believ bhvn initi focu acut care set
posit address larg patient pool
interest near-term catalyst import catalyst view
rimegep safeti data phase top-lin result oral dissolv tablet
acut migrain patient troriluzol phase data obsess compuls
disord ocd anticip next month
clariti commerci strategi critic oper expens estim
assum enter commerci partnership therefor model sale
market expens associ new launch event
commerci asset without partner note potenti fund
need late oper risk associ new commerci
earli pipelin provid long-term upsid intranas formul cgrp
receptor antagonist asset orphan indic rett syndrom
multipl system atrophi could valu enhanc longer term
biohaven develop therapi central
nervou system diseas current
platform two molecul glutam
modul platform three molecul
myeloperoxidas inhibitor platform
one molecul
analyst certif import disclosur see disclosur
believ
reflect current trade level outperform
thesi partial base under-the-radar glutam
platform two late stage asset well cgrp
receptor antagonist platform rimegep lead
acknowledg competit market dynam surround
mechan believ pursu indic
larg therapeut area accommod multipl player
like diversifi portfolio manag clinic
strategi note clariti commerci front could becom
import pipelin near regulatori mileston
rimegep launch nurtec launch
troriluzol launch ocd/ad sca
meaning increas near-term expens modest
increas sales/market expens
net oper loss nol balanc offset
annual taxabl incom tax rate thereaft
long-term safeti data rimegep
phase rimegep data
phase data social anxieti
troriluzol phase data ocd
rimegep nda submiss
troriluzol futil analysi alzheim phase studi
troriluzol clinic data ocd/ad and/or sca
superior long-term safeti data rimegep
nurtec approv launch
commerci partnership rimegep
neg troriluzol clinic data ocd/ad
target price base blend discount cash flow sum-of-the-part analys model sale lead product candid
ten-year period assum termin valu base tail product post project period use discount
rate believ approxim compani weight averag cost capit base risk-fre rate expect
market return beta per bloomberg partnership risk premium assum termin valu growth rate
revenu retain termin period
downsid risk includ rimegep long-term safeti risk neg troriluzol clinic data ocd/ad higher oper
expens potenti dilut fund
biohaven pharmaceut biopharmaceut compani focus
develop therapi central nervou system diseas compani
take platform-bas approach product develop current
platform two molecul glutam modul platform three
molecul myeloperoxidas inhibitor platform one molecul exhibit
manag highlight sever clinic catalyst next
month exhibit import view rimegep safeti
data acut migrain patient top-lin result phase oral
dissolv tablet trial acut migrain patient phase data
obsess compuls disord ocd
note pleas see initi report inc
platform product phase indic cgrp platformrimegep tablet treatment migrain rimegep treatment migrain rimegep tablet migrain nasal spray treatment prevent migrain troriluzol capsul disord ocd troriluzol capsul ataxia sca troriluzol capsul diseas ad troriluzol capsul anxieti disord gad nurtec sublingu later sclerosi capsul syndrom neuropsychiatr indic myeloperoxidas inhibit platform tablet atrophi glutam platform productpotenti mileston eventstimingrimegep top-line data long-term safeti studi acut migrain top-line result phase acut migrain phase migrain prevent trial nda amyotroph later sclerosi data obsess compuls disord ocd patient tablet nda submiss acut migrain futil analysi phase alzheim diseas studi phase studi spinocerebellar ataxia biohaven inc
glutam platform offer multipl shot goal
bhvn glutam modul platform includ candid two differ
mechan troriluzol glutam transport modul
glutam n-methyl-d-aspart nmda receptor antagonist
believ troriluzol could becom import valu driver next year
acknowledg sever clinic regulatori mileston need
met believ troriluzol revenu potenti larg
neuropsychiatry/neurodegen market ocd alzheim diseas
troriluzol offer pipelin molecul
troriluzol prodrug riluzol glutamaterg modul
neuroprotect plastic enhanc properti riluzol approv
amyotroph later sclerosi al use indic
remain under-explor primarili due dose-depend liver toxic
pharmacokinet variabl gastrointestin advers event troriluzol may
offer sever advantag rel riluzol includ improv bioavail
reduc risk liver toxic once-daili dose dose flexibl
limit clinic data troriluzol neuropsychiatr disord note pk
profil appear superior riluzol base mous model studi compar
riluzol direct oral dose mg/kg troriluzol oral dose mg/kg
exhibit acknowledg shortcom comparison note
troriluzol demonstr improv safeti profil clinic studi
molecul may posit address riluzol limit clinic treatment
exhibit riluzol troriluzol pk profil comparison
simoneaux richard evalu trigriluzol checkpoint inhibitor cancer patient oncolog time dec volum number page
explor troriluzol use multipl indic phase clinic
trial await data readout note approv treat one
condit could present meaning commerci opportun exhibit
market potenti estim base symphoni trx price current brand product per price rx
compani materi oppenheim co inc biom tracker clinicaltri gov
orphan
compani pursu varieti indic clinic trial
troriluzol value-inflect catalyst could occur manag decid
whether pursu orphan market larger commerci market
conserv assum one commerci strategi may viabl
near term valuat assum likelihood
commerci neuropsychiatric/neurodegen indic ocd ad
likelihood commerci orphan indic sca
probabl adjust reflect clinic risk commerci
consider highlight exhibit
unadjustedind revenuesmild/ moder ad ataxia sporadicataxiaessentialtremor otherataxia associ w/ cerebellar disord socialanxieti generalizedanxieti disorderbipolardepressionprodromaladcommerci without partnerorphandrug exclus ip protect premiumpr negoti leveragecontrol life cycl managementcommerci partnership termsip protect price pressur potentiallyr partner life cycl manag label expans clinic likelihood commerci file approv retain econom clinic likelihood commerci file approv retain econom expansionconsiderationvaluationvaluationconsiderationexpans biohaven pharmaceut inc
prior clinic trial riluzol fund refractori ocd patient
suggest riluzol may margin clinic benefit patient exhibit
note effect size outpati cohort promis howev data
demonstr meaning clinic benefit studi small
power show statist signific also constrain dose
limit riluzol
exhibit pilot placebo-control trial riluzol refractori ocd
pitteng bloch mh wasylink et al riluzol augment treatment-refractori obsessive-compuls
disord pilot placebo-control trial clin psychiatri press
bioavail reduc drug burden favor safeti profil once-daili
dose may posit becom commerci viabl pharmacolog
agent clinic trial demonstr efficaci
seat cgrp tabl
believ bhvn migrain strategi target broad rang patient need
vari cgrp calcitonin gene-rel peptid formul includ oral
tablet oral dissolv tablet intranas spray acut
prevent market rimegep bhvn lead cgrp asset may market
tablet formul acut migrain treatment bhv-
intranas formul may earli stage clinic trial migrain
prevent believ multipl player could compet effect
migrain market note bhvn initi focu acut care set
posit address larger patient pool
larg episod migrain market room multipl player
estim adult us suffer acut migrain exhibit
studi placebo bid weeksprimari improv baselin y-boc scorein particip outpatientsinclusionmoder sever refractori ocd y-boc outperform
oppenheim co inc estim us censu resourc
estim episod migrain em patient may readili avail
treatment cgrp receptor antagonist near term exhibit
burch et al preval impact migrain sever headach unit state exhibit trend govern studi
migrain research foundat state women men suffer migrain use average exclud children
lipton rb bigal diamond et al migrain preval diseas burden need prevent therapi neurolog
chronic migrain migrain headach headach suffer adult adult adult w/ migraine/sever us adult w/ migraine/sever headach w/ episod migrain em adult em adult rate migrain patient need prevent em patient need prevent patient avail acut triptan inelig inelig patient elig uncontrol triptan triptan cgrp acut care relat attribut episod migrain patient biohaven inc
assum price pariti current market cgrp monoclon
antibodi aimovig ajovi emgal estim us revenu potenti
novel acut migrain therapi exhibit
believ bhvn rimegep could compet effect episod
migrain market may includ other develop agn
ubrogep lli lasmiditan well current market therapi
pharmacolog class exhibit
exhibit acut episod migrain drug
market product sale includ gener competitor
acut care cgrp patient per patient per month dose per patient per year rate dose per patient per year script per patient per per patient per price per patient per per patient per oral cgrp us market potenti target compani ltm sale symtouchserotonin receptordr reddi receptorglaxosmithklin receptormerck co receptorpf receptoramn pharmaceut apr appli pharma research dopamin serotonin receptorsbausch health compani serotonin receptorpernix therapeut hold xsailserotonin receptorotsuka hold co doseproserotonin receptorendo intern receptorglaxosmithklin receptorendo intern receptorjohnson odfserotonin receptorapr appli pharma research sanasempranaadrenerg serotonin receptorsallergan receptordr reddi laboratorieslasmiditanserotonin receptor lilli companyrizaportserotonin receptorsintelgenx technolog corp ubrogepantcgrp receptorallergan reddi receptorzosano pharma receptorsimpel neuropharma inc market brandsfil phase outperform
rimegep gener par novel therapi
base avail clinic data exhibit discuss migrain
kol key opinion leader believ rimegep may perceiv
clinic par agn ubrogep safer lli lasmiditan
view assum label price pariti new launch rimegep
could becom import therapeut altern migrain patient also
note rimegep may offer margin conveni advantag
measur hour first dose
uln upper limit normal
addit lead asset rimegep troriluzol note
asset pipelin factor valuat specif
portfolio includ intranas formul cgrp receptor antagonist bhv-
may enter clinic migrain prevent asset
antagonist rett syndrom phase myeloperoxidas inhibitor bhv-
multipl system atrophi
target price base blend discount cash flow exhibit
sum-of-the-part exhibit analys model sale lead product
candid ten-year period assum termin valu base
tail product post project period assumpt underli
price target
rimegep launch patient share reach outer
nurtec launch script share grow
troriluzol launch ocd/ad adjunct therapi script
share grow indic sca launch
model nurtec rimegep revenu probabl
troriluzol probabl ocd/ad probabl sca
model rimegep gross margin assum partnership
nurtec troriluzol gross margin ocd/ad assum
partnership sca
assum near-term increas expens
assum modest sales/market expens nurtec begin
use net oper loss nol balanc carri off-set
annual taxabl incom use tax rate thereaft
discount cash flow year-end discount rate
believ approxim compani weight averag cost
capit base risk-fre rate expect market return
beta per bloomberg partnership risk premium
termin valu growth rate revenu retain
summaryrevenu profit incom tax after-tax work cash flow per share discount rate current valu valu valu cash valu rate growth rate outperform
key driver valuat price target rimegep troriluzol
asset meaning near-term clinic catalyst import
view long-term safeti data rimegep acut migrain patient
phase data troriluzol
rimegep safeti data form key compon new drug
applic nda manag expect file fairli
confid safeti data studi would reflect phase trial
report previous expect investor compar data agn ubrogep
expect signific upsid posit readout anticip
downsid price target safeti data subpar refer
everi year launch delay estim neg impact price
note troriluzol use ocd/ad account approxim one-third
price target expect top-line data phase trial ocd
clinicaltri gov indic primari complet limit clinic
data avail troriluzol use neuropsychiatr indic fairli
conserv low probabl success indic failur
ocd could impli clinic risk program ad gad given
view glutam platform valu reflect stock present
believ may limit downsid stock neg readout
howev would impli downsid price target
oper expens estim assum enter commerci
partnership rimegep migrain treatment troriluzol ocd/ad
treatment model rimegep gross margin assum partnership
nurtec troriluzol gross margin ocd/ad assum
partnership sca therefor model sale market
expens associ two asset event commerci
asset without partner note potenti risk associ
fundrais potenti dilut current sharehold
high prescrib primari care physician rimegep
make attempt quantifi impact strateg decis
note sever variabl consid could creat
variabl estim
absenc partnership estim may need rais
fund manag pursu equiti financ estim theoret
studi achiev ii patient complet treatment day consecut treatment altern day placebo trial durat week total number dose natot number migrain attack namean number migrain attack oropharyng pain nasopharyngitisdrug-induc liver injuri nono advers event upper respiratori tract infectionsinus urinari tract infect treatment everi year outperform
dilut impact per share price target assum issuanc
price slightli current trade level per share els equal
absenc cgrp partnership may need build fairli
substanti commerci infrastructur estim preliminarili sale
market spend grow outer year
may enter migrain market compet sever larg
pharmaceut compani significantli resourc commerci
expertis well sever generic treatment option note
potenti second entrant oral episod migrain market expect file
earli may face higher hurdl payer front also note
potenti cgrp-mab teva ajovi amgn aimovig lli
emgal captur signific mindshar next coupl year
intern headach societi standard provid distinct definit
chronic migrain vs acut migrain patient kol check suggest
mainli meant research set rare use clinic practic
therefor like prescrib may opt prevent treatment
larger subset patient one expert treat migrain
patients/month tertiari headach center note even patient present
migrain per month experi non-migrain headach
remaind month need treat therefor may elig
model rimegep revenu grow outer
year probabl adjust see exhibit note everi reduct
revenu estim theoret lower price target
manag prior experi educ vlad coric chief yale clinic neurosci research unitceo directordirector yale obsessive-compuls disord research clinicpresid connecticut psychiatr societym wake forest univers school medicin jim engelhartexecut director chief officerb account villanova univers charli conway ph lead scientist bristol-my squibb compani bm chief scientif officerph neurosci univers california santa barbara outperform
compani materi oppenheim co inc estim
quarterli revenu revenu chang rimegep nananananananananananurtec ocdnanananananananananatroriluzol adnanananananananananatroriluzol scananananananananananatot revenu nananananananananana revenu rimegep revenu earn revenu profit incom expens incom tax rate incom incom common sharehold ep share changetot revenuenanananananananananacogsnanananananananananagross outperform
compani materi oppenheim co inc estim
annual revenu revenu chang rimegep revenu revenu rimegep revenu earn revenu profit incom expens incom tax rate incom incom common sharehold ep share changetot outperform
sheet cash equival cash expens current asset current asset method invest tax asset offer cash asset asset payabl net current liabil liabil liabil equiti liabil payabl relat parti relat sale futur royalti net long-term liabil liabil sharehold equiti liabil sharehold equiti biohaven inc
stock price compani mention report
